

the mother nucleus and the left side of the group Y is bound to benzene nucleus;

X represents $[=CH-]_nCH$;

n is 0, 1, 2, 3 or 4;

Z represents 4-methylpiperazino, 4-methylhomopiperazino, piperidino, pyrrolidino, thiomorpholino, morpholino or $-NR_6R_7$ wherein R_6 and R_7 are the same or different and represent hydrogen atom or a lower alkyl;

[--- means single bond or double bond;]

and the pharmaceutically acceptable salts thereof.

REMARKS

Claim 1 has been amended to better conform with accepted U.S. practice, and to adopt the Examiner's request that the erroneous definition of the bond linking X to the oxepin nucleus be deleted.


Claims 1-10 and 13-19 stand rejected under 35 U.S.C. § 102 as anticipated or under 35 U.S.C. § 103 as obvious over Japanese laid-open patent application No. 62-45557, as illustrated by Chem. Abs., Vol. 107 (1987) 58673r. These rejections are respectfully traversed. Applicants note that the cited Japanese application was not laid-open until February 27, 1987, after the March 3, 1986 priority date of the present invention. Accordingly,

submitted herewith is a certified translation of Applicants' Japanese priority patent application No. 86-45676. Therefore, Japanese laid-open patent application No. 62-45557 is no longer citable prior art and the rejection based thereon should be withdrawn.

Claims 1-10 and 13-19 remain in prosecution.

In view of the above amendments, remarks and the accompanying certified translation of Japanese patent application No. 86-45676, reconsideration and allowance of this application are earnestly solicited.

Respectfully submitted,


Nels T. Lippert
Attorney for Applicants
Registration No. 25,888

FITZPATRICK, CELLA, HARPER & SCINTO
277 Park Avenue
New York, New York 10172
(212) 758-2400

1208U/lab